Hepatitis C virus (HCV) is a major cause of liver disease and hepatocellular carcinoma
worldwide. HCV establishes a chronic infection in the majority of cases. However, some …

Hepatitis C virus (HCV) remains a public health problem of global importance, even in the
era of potent directly-acting antiviral drugs. In this chapter, I discuss immune responses to …

The contribution of humoral immune responses to spontaneous control of hepatitis C virus
(HCV) infection remains unclear. We assessed neutralizing antibody (nAb) responses …

The majority of broadly neutralizing antibodies to hepatitis C virus (HCV) are against
conformational epitopes on the E2 glycoprotein. Many of them recognize overlapping …

Hepatitis C virus (HCV) infection is a leading cause of liver transplantation and there is an
urgent need to develop therapies to reduce rates of HCV infection of transplanted livers …

Hepatitis C virus (HCV) infects more than 2% of the global population and is a leading cause
of liver cirrhosis, hepatocellular carcinoma, and end-stage liver diseases. Circulating HCV is …

ABSTRACT A challenge for hepatitis C virus (HCV) vaccine development is defining
conserved epitopes that induce protective antibodies against this highly diverse virus. An …

Exosomes are gaining prominence as vectors for drug delivery, vaccination, and
regenerative medicine. Owing to their surface biochemistry, which reflects the parent cell …

The high mutation rate of hepatitis C virus allows it to rapidly evade the humoral immune
response. However, certain epitopes in the envelope glycoproteins cannot vary without …

Virus neutralization (VN) responses range from narrowly focused antibodies with only
homologous neutralizing activity against the virus used for infection, to antibodies that can …